James Kelly has served as our Executive Vice President, Chief Financial Officer since October 2020. Previously, Mr. Kelly was Executive Vice President, Chief Financial Officer of Vanda Pharmaceuticals, a public biopharmaceutical company where he served as Chief Financial Officer from 2010 to 2020. Mr. Kelly held finance roles at Medimmune, a biotechnology subsidiary of the AstraZeneca Group from 2006 to 2010, most recently as Vice President, Controller. From 2000 to 2005, Mr. Kelly was at Biogen serving in research & development finance roles of increasing responsibility, most recently as Director of Planning and Operations. From 1997 to 2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc. responsible for mergers and acquisitions and treasury management. He began his life sciences career in 1991 with Janssen Pharmaceuticals, a division of Johnson & Johnson. Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers. He received his Bachelor of Sciences degree in Business Administration from the University of Vermont and his Master of Business Administration degree from Cornell University.